graphicola
- Royalty Pharma (NASDAQ:RPRX) announced Wednesday $511M in monetization proceeds received from the sale of remaining fixed payments linked to Development Funding Bonds issued by the recent Novartis (NVS) buyout MorphoSys in 2022.
- The transaction with an unnamed syndicate of investors